176 related articles for article (PubMed ID: 33816783)
1. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.
Kubo H; Yagyu S; Nakamura K; Yamashima K; Tomida A; Kikuchi K; Iehara T; Nakazawa Y; Hosoi H
Mol Ther Oncolytics; 2021 Mar; 20():646-658. PubMed ID: 33816783
[TBL] [Abstract][Full Text] [Related]
2. Autologous antigen-presenting cells efficiently expand
Nakamura K; Yagyu S; Hirota S; Tomida A; Kondo M; Shigeura T; Hasegawa A; Tanaka M; Nakazawa Y
Mol Ther Methods Clin Dev; 2021 Jun; 21():315-324. PubMed ID: 33898630
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in
Morita D; Nishio N; Saito S; Tanaka M; Kawashima N; Okuno Y; Suzuki S; Matsuda K; Maeda Y; Wilson MH; Dotti G; Rooney CM; Takahashi Y; Nakazawa Y
Mol Ther Methods Clin Dev; 2018 Mar; 8():131-140. PubMed ID: 29687032
[TBL] [Abstract][Full Text] [Related]
5. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
6. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME; Cleary MM; Bajwa Z; Svalina MN; Young MC; Mansoor A; Kaur P; Bult CJ; Goros MW; Michalek JE; Xiang S; Keck J; Krasnoperov V; Gill P; Keller C
PLoS One; 2017; 12(8):e0183161. PubMed ID: 28817624
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
9. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
[No Abstract] [Full Text] [Related]
11. Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Kawahara Y; Furuta T; Sabit H; Tamai S; Dong Y; Jiapaer S; Zhang J; Zhang G; Oishi M; Miyashita K; Hayashi Y; Nakada M
Cancer Lett; 2019 May; 449():56-65. PubMed ID: 30776480
[TBL] [Abstract][Full Text] [Related]
12. A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells.
Yagyu S; Mochizuki H; Yamashima K; Kubo H; Saito S; Tanaka M; Sakamoto K; Shimoi A; Nakazawa Y
Clin Transl Immunology; 2021; 10(6):e1291. PubMed ID: 34123382
[TBL] [Abstract][Full Text] [Related]
13. Autologous non-human primate model for safety assessment of
Morokawa H; Yagyu S; Hasegawa A; Tanaka M; Saito S; Mochizuki H; Sakamoto K; Shimoi A; Nakazawa Y
Clin Transl Immunology; 2020; 9(11):e1207. PubMed ID: 33251009
[TBL] [Abstract][Full Text] [Related]
14. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
15. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
16. Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.
Štach M; Ptáčková P; Mucha M; Musil J; Klener P; Otáhal P
Cytotherapy; 2020 Dec; 22(12):744-754. PubMed ID: 32950390
[TBL] [Abstract][Full Text] [Related]
17. Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers.
Chinsuwan T; Hirabayashi K; Mishima S; Hasegawa A; Tanaka M; Mochizuki H; Shimoi A; Murakami T; Yagyu S; Shimizu K; Nakazawa Y
Mol Ther Oncolytics; 2023 Dec; 31():100728. PubMed ID: 37822488
[TBL] [Abstract][Full Text] [Related]
18. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.
Caruso HG; Tanaka R; Liang J; Ling X; Sabbagh A; Henry VK; Collier TL; Heimberger AB
J Neurooncol; 2019 Dec; 145(3):429-439. PubMed ID: 31686330
[TBL] [Abstract][Full Text] [Related]
19. Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells.
Tay JCK; Wang J; Du Z; Ng YY; Li Z; Ren Y; Zhang C; Zhu J; Xu XH; Wang S
Mol Ther Methods Clin Dev; 2021 Jun; 21():107-120. PubMed ID: 33816644
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]